Craig R. Travis, M.D., Although he had been a practicing board certified emergency physician for more than forty years, the six years which he spent in Negril Jamaica from 1988 until 1994, had made the most lasting impression on his life - working with limited resources not only increased his clinical acumen but confronted him with cultural norms which challenged conventional wisdom, particularly about the widespread use of cannabis especially in the context of the global pandemic of HIV. It was in his practice there that he treated sexually transmitted diseases on a daily basis yet was aware of the astonishingly low prevalence of HIV on the island. In 1991, he suggested in a letter to The National AIDS Foundation of Jamaica that the use of marijuana could be masking the true prevalence of the disease by contributing to a quiescent state of the immune system which would be unfavorable to the transmission and/or progression of the disease.
While practicing there he established The Stretcher Board Program, a prototypic first responder program in Negril which laid the groundwork for the development of the island’s first emergency medical system. As a founding member of the Negril Coral Reef Preservation Society and Fshermen’s Cooperative, Negril now has a Marine Park.
As an inventor and innovator, he has won four patents for the use of synthetic, non-psychoactive derivatives of THC for the treatment and prevention of HIV. Given his deep understanding of the pharmacologic activities of this class of drugs, he will be submitting additional patent applications for other novel uses of the drugs which have not been disclosed in previous patents nor the scientific literature.
Although he strongly believes in the need for patent exclusivity, he also believes that such a monopoly could lead to the lower costs of drugs especially when there is a threat such as HIV/AIDS and address the issue of the costs of essential drugs on a global basis. Despite the fact that antiretroviral therapy has been a great scientific discovery and continues to have benefit, its limitations and failures can only be attributed to its high costs, poor compliance and lack of availability where it is greatest demands remain unmet - the developing world.
Dr. Travis is fortunate to have assembled an outstanding scientific advisory board, management team and board of directors. With their support, he will be able to focus on the specific achievable goals which will make the use of the lead compounds a reality on a global basis over the next three to five years.
Dr. Massey is a neuropharmacologist, pharmacogeneticist, life sciences professional, senior executive and entrepreneur. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences and subsequently was an investigator at the Pritzker School of Medicine’s Drug Abuse Research Center at The University of Chicago. Dr. Massey holds long-standing adjunct faculty appointments at the University of Arkansas for Medical Sciences (Associate Professor, Dept. of Pharmacology and Interdisciplinary Toxicology) and the University of Mississippi Medical Center (Clinical Assistant Professor, Dept. of Psychiatry).
Dr. Massey has previously held leadership positions at Merck, Astra Merck, Quintiles, Scirex, Astra Zeneca, Scientific Commercialization, Litmus Molecular Design, SureGene, and GeneAlign. He has played a leadership role placing 28 new drugs into human testing and in bringing 8 new drugs onto the market. Dr. Massey held the Jack Martin, MD Research Professorship in Psychopharmacology at Vanderbilt University, where he conducted research into the genetics, biological basis and pharmacological treatment of schizophrenia and serious mental illness in collaboration with Dr. Herbert Y. Meltzer. Dr. Massey has also served as Chief Science Officer at Opiate Treatment Centers of America. In addition to his position with CadiraMD, Dr. Massey is currently a Visiting Scholar at the Feinberg School of Medicine’s Dept. of Psychiatry and Human Behavior at Northwestern University where he continues his research collaboration with Dr. Meltzer.
Dr Dorothy Bray is a Senior Executive and Entrepreneur in biopharmaceutical industry with over 25 years experience in healthcare. In the past she served as a Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline and also as Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA and as Principal Clinical Research Scientist at Antivirals, Glaxo Wellcome, UK and USA. In addition to her major pharmaceutical industry activities she served as a Member of the Scientific Staff and the Head of Scientific Business Development of The UK Medical Research Council Clinical Trials Unit, currently holds an honorary Senior Lecturer position at the University of London and serves as a reviewer for a number of scientific journals. She is also the European Commission's Scientific Expert and acts as a business advisor to investment companies in USA and Europe.
Dr Bray has extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and emerging markets. Dr Bray works with a number of biotechnology and nutraceutical companies helping to develop the commercial and clinical development strategy. In Since 2012 Dr Bray has been involved in helping companies, research institutions and governments to establish legal hemp and cannabis programmes, from industrial applications like fibre production and building materials, fuels and plastics to developing novel formulations for pure compounds and crude extracts to deliver precise oral dosing of cannabinoids in the multiple therapeutic applications. Additionally, she is an inventor with multiple patents.
Specialties: Business development, pre-clinical and clinical strategy to develop novel pharmaceuticals, nutraceuticals and functional food products, solutions for conditions related to ageing, including inflammation.
In addition to serving as Immugen's Chief Financial Officer, David founded and has served as Chief Executive Officer of ALDA & Associates International, a management services firm focused on life sciences and healthcare since its inception in January 1993. Since 1993, his experience resulted in the development of broad relationships with physicians and physician groups across the country. Prior to the formation of ALDA he was an international business advisor to senior management and boards of directors as a senior international partner during a 24-year career with Ernst & Young from January 1969 to December 1992. His book Essentials of Corporate and Capital Formation was recently published by Wiley & Sons. David is a Certified Public Accountant.
Craig R. Travis, M.D., Chairman and Founder
Bill Massey, Ph.D.
Dorothy Bray, Ph.D.
David Fater, CPA
Harold 'Hal' Haines, Ph.D. - Hal is the President and CEO of NuGenerex Diagnostics, which is a subsidiary of the public company, Generex Corporation (GNBT). NuGenerex Diagnostics is a company which develops and markets point-of-care diagnostic devices.
Dr. Haines has 45 years of executive managerial and consulting experience in the healthcare industry, with a broad background in pharmaceuticals, diagnostics, medical devices and therapeutics. He has led healthcare companies, provided technical and strategic business development expertise in the healthcare industry for biotechnology companies, pharmaceutical companies, diagnostic companies, medical practices and clinics, venture capital firms, legal firms, with emphasis on infectious diseases and oncology problems, products and services and natural products. He also has provided strategic business and scientific planning for international companies and non-profit organizations, including strategic planning for manufacturing and medical facilities and biomedical startups.
In the 1990’s, at the height of the HIV epidemic, and before anti-retroviral therapy was instituted, he was a founder and served as the Scientific Director of the Immunology and Retrovirology Research Institute (IRI), a non-profit AIDS research Institute in Miami, Florida, dedicated to the development of immunologic therapies for the treatment of HIV and AIDS.
He has participated in numerous HIV and AIDS programs in the United States and abroad and has been a consultant to and presenter and convener for World Health Organization and Pan American Health Organization conferences on HIV and AIDS and on Dengue virus epidemics.
He is a former tenured Professor of Pathology, Dermatology and Microbiology and Immunology at the University of Miami School of Medicine, Miami, Florida.